Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational dia…

Biotechnology

US, Austin [HQ]

News

Theses · Events · Sentiments

Sentiments

25-01-14 -45.40%

NEW YORK , Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, …

25-01-13 0.60%

NEW YORK , Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava …

25-01-09 0.60%

NEW YORK , Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava …

25-01-03 -45.40%

NEW YORK , Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, …

25-01-02 -30.00%

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. …

25-01-02 -30.00%

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. …

24-12-31 -45.40%

NEW YORK , Dec. 31, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, …

24-12-30 0.60%

NEW YORK , Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava …

24-12-26 0.60%

NEW YORK , Dec. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava …

24-12-25 -30.00%

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / If you suffered a loss on your Cassava Sciences, Inc. …